Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 22, Issue 5, Pages 609-615Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2010.08.006
Keywords
-
Categories
Funding
- MS Society of GB NI
- Wellcome Trust
Ask authors/readers for more resources
Nearly a century has passed since the first report describing antigen-specific immunotherapy (antigen-SIT) was published Research into the use of antigen-SIT in the treatment of both allergic and autoimmune disease has increased dramatically since although its mechanism of action is only slowly being unravelled It is clear though, from recent studies, that success of antigen-SIT depends on the induction of regulatory T (T reg) cell subsets that recognise potentially disease-inducing epitopes The major challenge remaining for the widespread use of antigen-SIT is to safely administer high doses of immunodominant and potentially pathogenic epitopes in a manner that induces T cell tolerance rather than activation This review illustrates that intelligent design of treatment agents and strategies can lead to the development of safe and effective antigen-SIT
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available